Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab.

These findings define the immunomodulatory factors CXCL11 and sMICA as predictive markers in melanoma patients least likely to benefit from treatment with the checkpoint inhibitor ipilimumab.